Open AccessOne-year outcomes of novel BioMime Morph tapered stent in long and multiple coronary artery lesions
Author(s) -
Yash Paul Sharma,
Lipi Uppal,
Prashant Panda,
Soumitra Mohanty,
Ganesh Kasinadhuni,
Darshan Krishnappa,
Saurabh Mehrotra,
Ankur Gupta,
Krishna Prasad,
Krishna Santosh,
Dinakar Bootla,
Soumitra Ghosh
Publication year - 2021
Publication title -
pubmed central
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.364
H-Index - 28
eISSN - 2149-2271
DOI - 10.5152/anatoljcardiol.2021.05763
Subject(s) - medicine , mace , stent , cardiology , myocardial infarction , conventional pci , lesion , coronary artery disease , percutaneous coronary intervention , artery , target lesion , coronary arteries , percutaneous , radiology , surgery
Even with the immense progress achieved in the field of percutaneous coronary interventions (PCIs), treatment of diffuse long atherosclerotic coronary artery disease continues to remain a challenge for durable outcomes. The downstream reduction in diameter along the lesion length of a coronary artery may compel the cardiologist to use either 2 overlapping stents of different diameters or a single long stent leading to stent-vessel mismatch at the edges. Recently, Meril Life Sciences Pvt. Ltd., India, has introduced a long-tapered sirolimus-eluting stent (SES) system, BioMime Morph, which conforms to the normal tapered geometry of coronary arteries along with adequate lesion coverage. In this study, we aimed to provide real world experience regarding the safety and efficacy of the BioMime Morph SES over a follow-up of one year.